Similarly, Zhang et al. found that hydroxycamptothecin reduces DNMT1 expression and downregulates the promoter methylation level of the p16 gene promoter, thereby increasing p16 expression in PBMCs from patients with SLE [76]. Here, DNMT1 is linked to systemic lupus erythematosus.